A328130 Stock Overview
Develops and provides AI based software solutions for cancer screening/diagnosis and treatment. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lunit Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩55,200.00 |
| 52 Week High | ₩100,500.00 |
| 52 Week Low | ₩31,000.00 |
| Beta | 1.82 |
| 11 Month Change | 42.45% |
| 3 Month Change | 19.48% |
| 1 Year Change | -38.87% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 176.00% |
Recent News & Updates
Shareholder Returns
| A328130 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | 28.1% | 38.0% | 2.3% |
| 1Y | -38.9% | -32.0% | -3.8% |
Return vs Industry: A328130 underperformed the KR Healthcare Services industry which returned -32% over the past year.
Return vs Market: A328130 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A328130 volatility | |
|---|---|
| A328130 Average Weekly Movement | 12.0% |
| Healthcare Services Industry Average Movement | 9.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A328130's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A328130's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 290 | Beomseok Brandon Suh | www.lunit.io |
Lunit Inc. develops and provides AI based software solutions for cancer screening/diagnosis and treatment. It offers AI solution for chest X-ray and mammography, as well as AI-powered biomarker for immune phenotyping and PD-L1 quantification for immunotherapy. The company was incorporated in 2013 and is based in Seoul, South Korea.
Lunit Inc. Fundamentals Summary
| A328130 fundamental statistics | |
|---|---|
| Market cap | ₩1.87t |
| Earnings (TTM) | -₩21.97b |
| Revenue (TTM) | ₩39.54b |
40.4x
P/S Ratio-72.7x
P/E RatioIs A328130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A328130 income statement (TTM) | |
|---|---|
| Revenue | ₩39.54b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩39.54b |
| Other Expenses | ₩61.51b |
| Earnings | -₩21.97b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -759.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -55.58% |
| Debt/Equity Ratio | 21.6% |
How did A328130 perform over the long term?
See historical performance and comparison